AP82 Stock Chart & Stats
€65970.00
€0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range€65,970.00 - €65,970.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€5.07M
Enterprise Value€393.91K
Total Cash (Recent Filing)€14.53M
Total Debt (Recent Filing)€4.42M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 06, 2026EPS Estimate
-5.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-357.16
Shares Outstanding1,246,105
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.41Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-20.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Multispecific PlatformAptevo’s ADAPTIR/ADAPTIR-FLEX multispecific antibody platforms represent a durable technical moat, enabling differentiated multi-specific therapeutics across oncology indications. Platform-driven candidate generation increases partnerability, supports multiple programs, and underpins recurring licensing or collaboration opportunities over time.
Compelling Clinical Validation In AMLStrong Phase 1b RAINIER results (high benefit/remission rates and favorable safety) materially de-risk mipletamig's development path and validate Aptevo's differentiated CD123 approach. Durable impact: supports orphan designation, strengthens strategic positioning vs standard of care, and improves attractiveness for partnerships or later-stage investment.
Pipeline Diversification Via Radiopharmaceutical CollaborationThe Niowave partnership diversifies Aptevo’s pipeline into targeted radiopharmaceuticals, combining multispecific antibodies with scarce isotope capability. Equity alignment and reciprocal IP/licensing broaden development resources, increase program optionality, and create a durable strategic avenue beyond conventional biologics.
Bears Say
Absent Revenue And Persistent LossesThe structural absence of recurring revenue combined with sizable TTM losses and cash burn means operations depend on external financing or milestone receipts. Over months this elevates dilution risk, constrains R&D sequencing, and limits the company's ability to self-fund multiple concurrent development programs without partnering or capital raises.
Negative Operating Cash Flow And Runway PressureSustained negative operating cash flow reflects limited internal funding capacity and ongoing burn. This structural cash deficit reduces strategic flexibility, can delay IND-enabling or pivotal studies absent new funding, and increases reliance on non-dilutive grants, partners, or dilutive financings to sustain operations over the next 2–6 months.
Clinical-stage Business Model With Binary OutcomesAs a clinical-stage biotech with no marketed products, Aptevo faces inherently binary development risk where long timelines and trial outcomes determine future cash flows. This structural profile makes revenue lumpy and unpredictable, heightens dependence on successful readouts or deals, and increases sensitivity to clinical setbacks.
Aptevo Therapeutics News
AP82 FAQ
What was Aptevo’s price range in the past 12 months?
Aptevo lowest stock price was €65970.00 and its highest was €65970.00 in the past 12 months.
What is Aptevo’s market cap?
Aptevo’s market cap is €5.07M.
When is Aptevo’s upcoming earnings report date?
Aptevo’s upcoming earnings report date is Aug 06, 2026 which is in 32 days.
How were Aptevo’s earnings last quarter?
Aptevo released its earnings results on May 07, 2026. The company reported -€5.602 earnings per share for the quarter, missing the consensus estimate of -€4.894 by -€0.708.
Is Aptevo overvalued?
According to Wall Street analysts Aptevo’s price is currently Undervalued.
Does Aptevo pay dividends?
Aptevo does not currently pay dividends.
What is Aptevo’s EPS estimate?
Aptevo’s EPS estimate is -5.26.
How many shares outstanding does Aptevo have?
Aptevo has 1,246,105 shares outstanding.
What happened to Aptevo’s price movement after its last earnings report?
Aptevo reported an EPS of -€5.602 in its last earnings report, missing expectations of -€4.894. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aptevo?
Currently, no hedge funds are holding shares in DE:AP82
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
AP82 Stock 12 Month Forecast
Average Price Target
€18.41
Options Prices
Currently, No data available
---